louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04367753: Predictive Factors for the Results of Epiphysiodesis in Limb Length Discrepancy
Official title: Predictive Factors for the Results of Epiphysiodesis in Limb Length Discrepancy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Limb Length Discrepancy
Keywords: Epiphysiodesis
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2020-04-29
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All minors with limb length discrepancy who had epiphysiodesis surgery

Brief summary: Several techniques exist for epiphysiodesis in limb length discrepancy with different results. Most of the time the results are disappointing for this functional surgery.

The aim of this study is understanding the reasons of the failures by analyzing the different steps of the medical care.

The patients will be distributed in two groups : "fulfilled contract" and "failed contract" The differences between the two groups will be analyzed.


Eligibility criteria: Inclusion Criteria:

* Patients with limb length discrepancy who had epiphysiodesis surgery

Exclusion Criteria:

* Missing x-rays
* missing data
* bone growth not achieved

Primary outcomes:
measure: Limb length discrepancy before surgery
timeFrame: 3 months
measure: Bones length
timeFrame: 3 months
measure: Predictive bone growth
timeFrame: 3 months
measure: Time limit between consultation and surgery
timeFrame: 3 months
measure: Screw position in physis
timeFrame: 3 months
measure: Bone age at the time of surgery
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHU Hopitâl d'Enfants
state: Lorraine
Study officials:
affiliation: CHU Hôpital d'Enfants Nancy
name: Mathias KIRSCH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04509453: McGRATH vs Macintosh Laryngoscopy Comparison in LMA Insertion
Official title: Comparison Between McGRATH and Macintosh Laryngoscopy in Laryngeal Mask Airway Insertion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intubation Complication
Intubation;Difficult
Anesthesia
Keywords: successful intubation
classic LMA
video laryngoscopy
difficulty
cuff pressure leak
Lead sponsor: Udayana University
Sponsor class: OTHER
First posted: 2020-08-12
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Various techniques have been developed to get a good LMA position, one of them is using a laryngoscope. The most popular laryngoscope used for LMA installation is the Macintosh type. Technological developments have brought laryngoscopes into the video era, one of which is McGRATH's laryngoscope, which from several studies about having an advantage in terms of the first attempt, time, complications, and hemodynamic stability of intubation. It needs to be proven through research on the comparison of clinical outcomes of LMA installation with McGrath laryngoscope and Macintosh laryngoscope.


Eligibility criteria: Inclusion Criteria:

* Patients underwent surgery with general anesthesia by LMA insertion in Sanglah General Hospital
* Agreed to be included in the study by signing informed consent
* American Society of Anesthesiologist physical status 1-2

Exclusion Criteria:

* Patients unfit for LMA insertion
* Patients with suspected airway management difficulty
* Pregnancy
* Morbid obese

Primary outcomes:
measure: Number of participants with first-attempt success
timeFrame: immediately after LMA insertion
measure: Mean arterial pressure
timeFrame: immediately after LMA insertion
measure: Heart rate
timeFrame: immediately after LMA insertion
Secondary outcomes:
measure: Time required
timeFrame: immediately after LMA insertion
measure: Complications
timeFrame: An hour after the the end of surgery
Other outcomes:
Locations:
city: Denpasar
country: Indonesia
facility: Sanglah General Hospital
state: Bali
Study officials:
References:
Clinical trial NCT00636753: Antipsychotics and Metabolic Syndrome
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Metabolic Syndrome
Keywords: Metabolic and endocrine changes in schizophrenic patients by antipsychotics treatment.
Lead sponsor: Glostrup University Hospital, Copenhagen
Sponsor class: OTHER
First posted: 2008-03-14
Enrollment: 60
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with debut of schizophrenia, controls from database

Brief summary: The purpose of the study is to determine whether antipsychotic treatment is influence psychiatric patients due to endocrine and metabolic status and quality of life.


Eligibility criteria: Inclusion Criteria:

* Gender male
* Age 18-45
* Debut drug-naive schizophrenics,
* Caucasians
* Consent given to take part in the project

Exclusion Criteria:

* Compliance-problems
* Major lung-/kidney/hart/lever disorders
* Abuse of alcohol/drugs
* Diabetes 1 and 2
* Antihypertensive
* Anticholesterol-reducing medication
* Patients under duress

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen, Nordre Ringvej 28-69
country: Denmark
facility: Psychiatric Center Glostrup
state: Glostrup
city: Nordre Ringvej 28-69
country: Denmark
facility: Psychiatric Center Glostrup
state: Glostrup
Study officials:
References:
Clinical trial NCT03123653: To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.
Official title: To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hepatitis B
Lead sponsor: Institute of Liver and Biliary Sciences, India
Sponsor class: OTHER
First posted: 2017-04-21
Enrollment: 118
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: * Study population:Person with HBeAg negative CHB on TDF/ETV for more than 1 year
* Study design:Prospective,Interventional (single arm study)
* Sample size: All the patients fulfilling the inclusion criteria will be included in first 6 months and subsequently followed up for 2 years
* Intervention: Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
* Monitoring and assessment: LFT,HBV DNA and HbsAg at baseline, 4 weeks, 12 weeks,24 weeks,48 weeks ,72 weeks and 96 weeks, CBC every month and Thyroid function Test every 3rd month
* Adverse effects: The most frequently reported side effects of IFN-based therapy are flu-like symptoms, headache, fatigue, myalgia, alopecia, and local reaction at the injection site. Peg-IFN have myelosuppressive effects; however, neutropenia\\1000/mm3 and thrombocytopenia \\500,000/ mm3 are not common unless patients already have cirrhosis


Eligibility criteria: Inclusion Criteria:

- HBeAg negative Chronic HBV infection who are having HBV DNA-undetectable. ALT \<40 IU/ml No Advanced fibrosis\[LSM \<14 KPa\] TDF/ETV \>1 year Clinical Relapse after stopping NA will be defined as HBV DNA\>2000IU/ml and ALT \> 80IU

Exclusion Criteria:

- HBeAg+ CHB Pregnancy Cirrhosis on biopsy or LSM \>14 Co-infection- HIV/HCV/HDV Immunosuppressive therapy Renal failure S.Bilirubin\>2mg/dl Patient having neutropenia

Primary outcomes:
measure: Sustained Virological Response-HBV DNA<2000IU/ml after stopping PEG IFN alpha
timeFrame: 6 months
Secondary outcomes:
measure: Loss of HBsAg after 48 weeks of PEG IFN alpha
timeFrame: 48 weeks
measure: End treatment Response: HBV-DNA -undetectable after 48 weeks of PEG-IFN
timeFrame: 48 weeks
measure: Sustained Off treatment Virological response defined as No clinical relapse during 1 year follow up after stopping therapy
timeFrame: 1 year
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Institute of Liver and Biliary Sciences
state: Delhi
Study officials:
References:
Clinical trial NCT00149253: Pre-Emptive Analgesia Efficacy of Etoricoxib for Postoperative Pain
Official title: A Randomized, Double-Blind, Controlled Trial of Etoricoxib as a Pre-Emptive Analgesic for Abdominal Hysterectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: a Single-Dose of Etoricoxib
Post-Operative Morphine Consumption
Total Pain Relief Over 8 Hr(TOPAR8)
Post Transabdominal Hysterectomy
Keywords: Abdominal hysterectomy,
Etoricoxib,
morphine consumption,
pre-emptive analgesia
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2005-09-08
Enrollment: 50
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Taken together, studies of the value of pre-emptive analgesia are inconclusive. This randomized, double-blind, dose-ranging, placebo-controlled study was therefore designed to test that a reduction in post-operative morphine consumption can be achieved by a single-dose of etoricoxib before induction of anesthesia.

Detailed description: Patients undergoing transabdominal hysterectomy were randomized to a group taking a single dose (orally) of etoricoxib 120 mg (n = 18), etoricoxib 180 mg (n = 17) or placebo (n = 15) 2 hours before surgery under the same standardized general anesthesia. At the post-anesthetic care unit, intravenous morphine titration was given before starting self-controlled analgesia (PCA) device. Morphine consumption, pain relief score, sedative score, global evaluation score, and side-effects were recorded at 1, 2, 4, 8 and 24 h post-operatively. The primary end points were morphine consumption within 24-hr post-operatively and total pain relief over 8 h (TOPAR8). Patient global satisfaction was also assessed.

Eligibility criteria: Inclusion Criteria:

* The ASA I or II patients undergoing elective transabdominal hysterectomy with general anesthesia

Exclusion Criteria:

* Patients with history of opioid addiction or chronic pain
* Allergy to other nonsteroidal anti-inflammatory, or asthma
* Concomitant use of tricyclic antidepressants, opioid analgesics, antihistamines, tranquilizers, hypnotics, sedatives, or systemic corticosteroids
* Those unable to understand the principle of patient-controlled analgesia(PCA) device were excluded from the study

Primary outcomes:
measure: The primary end points were morphine consumption within 24-hr post-operatively
measure: and total pain relief over 8 h (TOPAR8).
Secondary outcomes:
measure: Patient global response to therapy
Other outcomes:
Locations:
city: KhonKaen University
country: Thailand
facility: Warporn Chau-in
state: KhonKaen
Study officials:
affiliation: Department of Anesthesiology, Faculty of Medicine,KhonKaen University,KhonKaen 40002, Thailand
name: waraporn chau-in, Asso Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01081353: Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin
Official title: An Open Label 4-Way Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Effervescent Aspirin in Healthy Adult Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pharmacokinetics
Keywords: Aspirin
Acetylsalicylic Acid
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2010-03-05
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To determine the bioequivalence of new formula of aspirin relative to the established commercial effervescent aspirin when taken orally by healthy adult subjects


Eligibility criteria: Inclusion Criteria:

* Healthy male and female subjects between 18 to 55 years of age inclusive with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight \>50 kg (110 lbs)
* Results of screening and clinical laboratory tests are within normal range or considered not clinically significant by the Principal Investigator or Sponsor
* Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or a double barrier and have a negative pregnancy test at Screening and Day 0 for each Dosing Period. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy
* Be willing to participate in all scheduled visits, treatment plan, laboratory tests and other trial procedures according to the clinical protocol

Exclusion Criteria:

* History of hypersensitivity to aspirin (ASA), Nonsteroidal Antiinflammatory Drugs (NSAIDs), acetaminophen and similar pharmacological agents or components of the products
* Eighteen to twenty year olds with a viral infection, with or without fever, at the time of dosing - Syndromes of asthma, rhinitis or nasal polyps
* Females who are pregnant or lactating
* Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (Over the counter (OTC) or prescription) 7 days prior to dosing or during the treatment period, other than trial treatment
* Smokers or currently consuming any type of tobacco product(s) including any smoking cessation nicotine-containing product (e.g., nicotine patch, nicotine gum)

Primary outcomes:
measure: Bioavailability of new formulation aspirin versus marketed effervescent tablets (500mg aspirin)
timeFrame: 24 hours
Secondary outcomes:
measure: Adverse event collection
timeFrame: 24 hours
Other outcomes:
Locations:
city: Hackensack
country: United States
state: New Jersey
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT06767553: Biliary Complication Rates in Living Donor Liver Transplantation: a Retrospective Comparative Study of Stent Versus Non-Stent Groups
Official title: Impact of Non-stenting Method with Mucosal Eversion on Biliary Complications Post-LDLT in a Mid-volume Center: a Propensity Score-Matching Analysis of Case-Control Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Liver Failure
Living Donor Liver Transplantation
Biliary Complications
Biliary Stents
Lead sponsor: Chungnam National University Hospital
Sponsor class: OTHER
First posted: 2025-01-10
Enrollment: 160
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study includes adult patients aged 19 to 80 years who underwent liver transplantation for liver disease at Chungnam National University Hospital. The study population consists of patients who received either biliary stent placement or no stent placement during the liver transplantation surgery. Data will be retrospectively reviewed to compare biliary complications between the two groups.

Brief summary: Despite technological advancements in living donor liver transplantation (LDLT), biliary complications (BC), including biliary anastomotic stricture (BAS) and bile leak (BL), remain unresolved issues that significantly affect patient outcomes. Biliary stenting has emerged as a potential method for reducing BC in LDLT procedures; however, their necessity remains debated. This study aimed to assess the necessity of biliary stenting by retrospectively comparing the bile duct complication rates in LDLT using duct-to-duct anastomosis with or without biliary stenting.


Eligibility criteria: Inclusion Criteria:

* Adults aged between 19 and 80 years at the time of liver transplantation.
* Patients who underwent liver transplantation surgery for liver disease performed by the Department of Surgery at Chungnam National University Hospital under the supervision of the principal investigator.
* Patients who signed the informed consent form before study registration (for future participants).

Exclusion Criteria:

* Patients who have not signed the informed consent form or have insufficient understanding of the clinical trial protocol, making it difficult to accurately express their intention to participate.
* Patients deemed unsuitable for participation in this clinical study by the investigator.

Primary outcomes:
measure: Incidence of Biliary Complications
timeFrame: Within 10 years after liver transplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Daejeon
country: Korea, Republic of
facility: Chungnam National University Hospital
Study officials:
References:
Clinical trial NCT04224753: INVSENSOR00027 Fall Detection Clinical Performance Study
Official title: INVSENSOR00027 Fall Detection Clinical Performance Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Masimo Corporation
Sponsor class: INDUSTRY
First posted: 2020-01-13
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study assesses INVSENSOR00027's clinical performance for fall detection.


Eligibility criteria: Inclusion Criteria:

* 18 to 45 years old
* Physical status of ASA I or II
* Subjects must be able to read and communicate in English
* Has signed all necessary related documents, e.g. written informed consent, volunteer payment form, confidentiality agreement
* Has completed Health Assessment Questionnaire and passed health assessment screening

Exclusion Criteria:

* Subject has any medical condition which in the judgment of the investigator, renders them inappropriate for participation in this study
* Inability to tolerate physical activities including jumping and fall simulation
* Nursing female volunteers
* Excluded at the Principal Investigator's discretion
* Refusal to take the pregnancy test (for female subjects)
* Positive pregnancy test for female subjects of child bearing potential. This is done for the safety of this population.
* Refusal to shave hair (chest) off areas where sensors will be applied (male subjects)

Primary outcomes:
measure: Sensitivity of INVSENSOR00027's Fall Detection.
timeFrame: 1-5 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Masimo Clinical Lab
state: California
Study officials:
affiliation: Masimo Corporation
name: Ahmed Alghazi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03381053: Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation
Official title: Prospective Multicenter Cohort Study to Compare Pathologic Type, NIH and WHO Criteria, and Mechanism of GIST Malignant Transformation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Method of Differentiating Benignancy and Malignancy, Grading and Staging for GIST
Keywords: GIST
Grading and Staging
Lead sponsor: Shanghai Zhongshan Hospital
Sponsor class: OTHER
Collaborators: name: Ruijin Hospital
name: Fudan University
name: Changhai Hospital
name: Shanghai Changzheng Hospital
name: Huashan Hospital
First posted: 2017-12-21
Enrollment: 3000
Sex: ALL
Minimum age (years): 14
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with GIST by pathology

Brief summary: Evaluate the reliability of morphology standards for GIST pathologic type, staging and grading by retrospective analyzing clinical data; on this basis, establish a GIST standardized and individualized treatment mode to maximum benefit GIST patients, avoid under- and over-treatment

Detailed description: 1. Retrospective analysis of GIST cases in the recent five years: the GIST clinical data of Fudan University Zhongshan Hospital from 2007 January to 2012 December were collected. By reviewing the HE slides, GIST was evaluated by 12 indicators, NIH scheme and WHO standard. Accomplish the gene sequencing of KIT, PDGFRA, B-raf, and SDH. Follow up the patients about their treatment and prognosis. Analyze and compare the advantages and disadvantages of the histomorphology indicators, NIH scheme, and WHO standard.
2. Organize the first multicenter prospective cohort study of GIST individualized treatment based on the histomorphology. Obtain the evidence of histological assessment for GIST by following up patients for 3 years.
3. Establish an evaluation criteria based on the morphology of GIST. Make objective evaluations about GIST tumor size, tumor location and gene mutation status in the prognosis estimate. Make rules to effectively guide individualized treatment of GIST.

Eligibility criteria: Inclusion Criteria:

* All patients pathologically diagnosed with GIST during the period from 2017 to 2020

Exclusion Criteria:

* Only have Biopsy diagnosis
* Only have Liver metastasis or peritoneal dissemination
* Received imatinib treatment before surgery

Primary outcomes:
measure: Number of participants with tumor recurrence
timeFrame: 3 years
measure: Number of participants with tumor metastasis
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: 180 Fenglin Road
state: Shanghai
Study officials:
affiliation: Shanghai Zhongshan Hospital
name: Hou Ying Yong, Doctor
role: STUDY_CHAIR
References: